Celltech and Chiroscience in pounds 700m biotech merger
Wednesday 16 June 1999
Celltech Chiroscience will be the UK's largest biotechnology company and the largest pharmaceuticals company after AstraZeneca, which is valued at pounds 45bn.
The all-paper deal follows the merger last month of cash-strapped biotech tiddlers Proteus and Therapeutic Antibodies. However, it is unusual in that unlike their peers, Celltech and Chiroscience have strong balance sheets and no apparent need to merge.
Dr John Padfield, Chiroscience's chief executive said the merger was driven by both companies' need for critical mass. "There's an arms race in drugs discovery and size matters," he said.
Peter Fellner, Celltech's chief executive who is to retain his role in the new group, said: "We will now be competing with some parts of what a major pharmaceutical company does, and our drug development pipeline will be equivalent too."
Celltech's strengths are in molecular biology and Chiroscience's is in its gene-based technologies.
Dr Padfield is leave the group on completion of the deal to join the board of Nycomed Amersham.
The discussions which led to yesterday's announcement began after John Jackson, Celltech's chairman who is to retain his role in Celltech Chiroscience, unexpectedly bumped into Chiroscience chairman Hugh Collum, who becomes deputy chairman, at breakfast in a London hotel last autumn.
Based on Celltech's closing price of 472.5p and market capitalisation of pounds 365m, the deal values Chiroscience at pounds 331m, or 293p per share, an 18.3 per cent premium to Monday's closing price of 259p. Chiroscience shareholders will receive 62 Celltech shares for every hundred Chiroscience shares.
The principal benefit of the merger will be the capability of the enlarged scientific base of 400 research staff to handle larger drug discovery projects. In addition, the broadened portfolio of drugs in development minimises the groups' dependence on the success of any one drug. The group said there would be few redundancies.
Analysts said Chiroscience stood to gain more from the deal because it had few premium products in its development pipeline to follow up Chirocaine, its anaesthetic formulation expected to reach the market by year-end.
Yesterday the group announced marketing agreements with Purdue Pharma and Abbott Laboratories, both US-based pharmaceuticals groups, to distribute Chirocaine in the US and Europe respectively. Celltech Chiroscience said its challenge now was to attract young, creative scientists who were traditionally flocked to smaller, entrepreneurial companies.
However, Mr Jackson hinted the days of the small biotech company were coming to a close and the group would be considering making acquisitions. "In a lot of boardrooms people will be thinking about doing deals now," he said. "People have been saying something was going to happen for several years. Until now, there's been almost a paralysis."
Outlook, page 19
- 3 Alton Towers crash: Four seriously injured and 16 guests trapped as Smiler ride carriages collide
- 4 Ann Summers survey reveals the UK's favourite sex position
Man on naked bike ride gets ejected after becoming aroused
Caitlyn Jenner's mother Ester thought her daughter, formerly known as Bruce Jenner, had transitioned for money
Charles Kennedy 1959-2015: A gifted, compassionate politician whose career was cut short by the 'demon drink' - latest news
Alton Towers crash: Four seriously injured and 16 guests trapped as Smiler ride carriages collide
Charles Kennedy dead: A guy once asked the Lib Dem leader who his favourite Muppet was and his letter response was wonderful
Thousands of teenage girls enduring debilitating illnesses after routine school cancer vaccination
Migrants in Kos: Photos show real tragedy after Brits abroad complain of 'awkward' holidays
British tourists complain that impoverished boat migrants are making holidays 'awkward' in Kos
Michael Gove determined to scrap the Human Rights Act – even if Scotland retains it
Threat to scrap Human Rights Act could see UK follow Nazi example, warns UN official
Church of England 'one generation away from extinction' after dramatic loss of followers
iJobs Money & Business
£30000 - £35000 per annum: Recruitment Genius: The UK's fastest growing, multi...
£70000 - £90000 per annum: Recruitment Genius: A Financial Reporting Manager i...
£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...
£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...